DK1697405T3 - LSA-5 leverstadium- og blodstadium-antigen fra Plasmodium falciparum, immunogent præparat omfattende dette antigen samt vacciner mod malaria - Google Patents

LSA-5 leverstadium- og blodstadium-antigen fra Plasmodium falciparum, immunogent præparat omfattende dette antigen samt vacciner mod malaria

Info

Publication number
DK1697405T3
DK1697405T3 DK04804433.3T DK04804433T DK1697405T3 DK 1697405 T3 DK1697405 T3 DK 1697405T3 DK 04804433 T DK04804433 T DK 04804433T DK 1697405 T3 DK1697405 T3 DK 1697405T3
Authority
DK
Denmark
Prior art keywords
antigen
stage
lsa
plasmodium falciparum
vaccines against
Prior art date
Application number
DK04804433.3T
Other languages
English (en)
Inventor
Pierre Druilhe
Karima Brahimi-Zeghidour
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK1697405T3 publication Critical patent/DK1697405T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205Plasmodium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK04804433.3T 2003-12-15 2004-12-15 LSA-5 leverstadium- og blodstadium-antigen fra Plasmodium falciparum, immunogent præparat omfattende dette antigen samt vacciner mod malaria DK1697405T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03293158A EP1544211A1 (en) 2003-12-15 2003-12-15 LSA-5 pre-erythrocytic stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria
PCT/EP2004/014848 WO2005058948A1 (en) 2003-12-15 2004-12-15 Lsa-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria

Publications (1)

Publication Number Publication Date
DK1697405T3 true DK1697405T3 (da) 2013-01-02

Family

ID=34486470

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04804433.3T DK1697405T3 (da) 2003-12-15 2004-12-15 LSA-5 leverstadium- og blodstadium-antigen fra Plasmodium falciparum, immunogent præparat omfattende dette antigen samt vacciner mod malaria

Country Status (9)

Country Link
US (1) US8765145B2 (da)
EP (2) EP1544211A1 (da)
JP (1) JP4991308B2 (da)
CN (1) CN1922202A (da)
BR (1) BRPI0417286A (da)
CA (1) CA2548792C (da)
DK (1) DK1697405T3 (da)
WO (1) WO2005058948A1 (da)
ZA (1) ZA200604958B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100982064B1 (ko) * 2006-03-28 2010-09-13 원광대학교산학협력단 말라리아 원충에 대한 단일클론 항체 및 이를 이용한말라리아의 진단방법
CN101603964A (zh) * 2009-07-10 2009-12-16 中国海洋大学 海产品中异尖线虫的酶联免疫检测方法
CA3002946C (en) * 2009-11-05 2021-11-02 The United States Of America As Represented By The Secretary Of The Navy Plasmodium falciparum sporozoite and liver stage antigens
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
WO2016084944A1 (ja) * 2014-11-28 2016-06-02 国立大学法人 群馬大学 熱帯熱マラリア原虫のエノラーゼタンパク質の部分配列を用いた人工抗原とその製造方法
MX2018014253A (es) 2016-05-19 2019-11-11 Univ Pennsylvania Inmunógenos de malaria sintéticos, combinaciones de estos y su uso para prevenir y tratar infecciones de malaria.
CN113144222B (zh) * 2021-04-14 2023-05-23 台州学院 外泌体用于防止脑型疟疾发生的实验方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566780B1 (fr) 1984-07-02 1987-02-06 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un epitope caracteristique d'une proteine produite par des cellules infectees par les parasites du paludisme et compositions les contenant
US20020076769A1 (en) * 2000-08-03 2002-06-20 Richard Brady Reduced molecular weight galactomannans oxidized by galactose oxidase
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens

Also Published As

Publication number Publication date
EP1697405B1 (en) 2012-09-05
JP2008504005A (ja) 2008-02-14
US8765145B2 (en) 2014-07-01
US20100183590A1 (en) 2010-07-22
CA2548792C (en) 2014-07-08
EP1544211A1 (en) 2005-06-22
BRPI0417286A (pt) 2007-04-10
WO2005058948A1 (en) 2005-06-30
EP1697405A1 (en) 2006-09-06
CN1922202A (zh) 2007-02-28
ZA200604958B (en) 2007-11-28
CA2548792A1 (en) 2005-06-30
JP4991308B2 (ja) 2012-08-01

Similar Documents

Publication Publication Date Title
IL181733A0 (en) Vaccines comprising plasmodium antigens
EP1708748A4 (en) INFLUENZA IMMUNOGENS AND VACCINES
NO20035208D0 (no) Nytt vaksine preparat
EP1569515A4 (en) MALARIA vaccine method
DK1946771T3 (da) Multivalent vaccinesammensætning
EP1603590A4 (en) INFLUENZA VIRUS VACCINE
CY2016018I2 (el) Εμβολιο κατα του ιου του δυτικου νειλου
EP1458242A4 (en) COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
CY2014010I1 (el) Εμβολιο δυτικου νειλου
EP1307130A4 (en) VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
EP1423141A4 (en) VACCINE
NO20041157L (no) HIV-GAG kodonoptimaliserte DNA-vaksiner
EP1572124A4 (en) HCV E1E2 VACCINE COMPOSITIONS
NO20033882L (no) Vaksine
EP1450752A4 (en) MULTIVALENT VACCINE COMPOSITIONS CONTAINING STREPTOCOCCUS AND METHODS OF USE
IS7831A (is) Bóluefni
ATE485833T1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
EP1435776A4 (en) VACCINE AGAINST CANCER AND DIAGNOSTIC PROCEDURE AND REAGENTS
DK1697405T3 (da) LSA-5 leverstadium- og blodstadium-antigen fra Plasmodium falciparum, immunogent præparat omfattende dette antigen samt vacciner mod malaria
EP1814393A4 (en) TOLEROGENIC VACCINATE AND METHOD
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus
AU2003278175A8 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
IS2922B (is) Bóluefni
AU2002304480A1 (en) Plasmodium falciparum antigens and vaccine and diagnostic uses thereof
DE10290185D2 (de) Tumorvakzine